| First Author | Sivaprakasam S | Year | 2021 |
| Journal | Biochem J | Volume | 478 |
| Issue | 7 | Pages | 1347-1358 |
| PubMed ID | 33720280 | Mgi Jnum | J:316279 |
| Mgi Id | MGI:6707865 | Doi | 10.1042/BCJ20210100 |
| Citation | Sivaprakasam S, et al. (2021) alpha-Methyl-l-tryptophan as a weight-loss agent in multiple models of obesity in mice. Biochem J 478(7):1347-1358 |
| abstractText | alpha-Methyl-L-tryptophan (alpha-MLT) is currently in use as a tracer in its 11C-labeled form to monitor the health of serotonergic neurons in humans. In the present study, we found this compound to function as an effective weight-loss agent at pharmacological doses in multiple models of obesity in mice. The drug was able to reduce the body weight when given orally in drinking water (1 mg/ml) in three different models of obesity: normal mice on high-fat diet, Slc6a14-null mice on high-fat diet, and ob/ob mice on normal diet. Only the l-enantiomer (alpha-MLT) was active while the d-enantiomer (alpha-MDT) had negligible activity. The weight-loss effect was freely reversible, with the weight gain resuming soon after the withdrawal of the drug. All three models of obesity were associated with hyperglycemia, insulin resistance, and hepatic steatosis; alpha-MLT reversed these features. There was a decrease in food intake in the treatment group. Mice on a high-fat diet showed decreased cholesterol and protein in the serum when treated with alpha-MLT; there was however no evidence of liver and kidney dysfunction. Plasma amino acid profile indicated a significant decrease in the levels of specific amino acids, including tryptophan; but the levels of arginine were increased. We conclude that alpha-MLT is an effective, reversible, and orally active drug for the treatment of obesity and metabolic syndrome. |
